Repligen | RGEN - 销售和管理费用



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 606.78M
销售成本
USD 94.09M
流动资产
USD 1.2B
流动负债
USD 132.66M
债务
USD 690.94M
EBIT
USD 21.13M
EBITDA
USD 43.77M
员工
1.78K
EPS每股收益
USD 0.54
股本和储备
USD 2.11B
销售毛利
USD 110.04M
债务利息支出
USD 5.66M
利息收入
USD 7.31M
贷款资金
USD 551.05M
市值
USD 9.28B
净收入
USD 5.01M
营业费用
USD 183M
营业利润
USD 21.13M
普通股股本
USD 56.43M
PE价格收益
105.09
税前利润
USD 14.15M
销售收入
USD 204M
销售和管理费用
USD 76.62M
股票
USD 186.6M
贸易债权人
USD 33.23M
应收帐款人
USD 157.71M


销售和管理费用 更改 日
Agilent USD 465M 11M 2026-03
Align Technology USD 462.67M 2.67M 2026-06
Bio Techne USD 109.34M 4.35M 2026-03
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Bruker USD 238.9M 3.2M 2026-06
Charles River Laboratories USD 228.9M 69.47M 2026-06
Danaher USD 2.07B 212M 2026-06
Dentsply International USD 364M 13M 2026-06
General Electric Aerospace USD 1.13B 47M 2026-06
Henry Schein USD 831M 22M 2026-06
Illumina USD 273M 1000K 2026-06
IQVIA Holdings USD 574M 72M 2026-06
Mettler Toledo International USD 263.33M 5.01M 2026-06
Myriad Genetics USD 122.3M 6.7M 2025-12
OraSure Technologies USD 13.21M 3.29M 2025-12
Pacific Biosciences Of California USD 37.24M 25.68M 2025-12
Pfizer USD 3.41B 496M 2026-06
Repligen USD 76.62M 82K 2026-06
Revvity USD 278.58M 24.69M 2026-06
Standard Biotools USD 18.61M 2.94M 2026-03
Thermo Fisher Scientific USD 1.91B 111M 2026-06
Waters USD 405M 11M 2026-06
West Pharmaceutical Services USD 117.6M 18.1M 2026-06